Synergy Pharmaceuticals' Reaches Enrollment Halfway Mark in Plecanatide Phase 2b Trial in IBS-C
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a developer of new drugs to
treat gastrointestinal diseases and disorders, today announced that it
has reached the halfway mark for total enrollment in its ongoing
plecanatide Phase 2b clinical trial in patients with irritable bowel
syndrome with constipation (IBS-C).
The study is being conducted at 70 sites in the United States and is
scheduled to include 350 patients with IBS-C. Over 600 patients have
been screened to date and 180 have been enrolled. The first patient was
dosed on December 27, 2012 and Synergy anticipates completing enrollment
in the fourth quarter of 2013 and reporting topline data in the first
quarter of 2014.